All AbMole products are for research use only, cannot be used for human consumption.
Andarine (GTX-007) is a selective nonsteroidal androgen receptor (AR) agonist with Ki of 4 nM. It is an investigational selective androgen receptor modulator (SARM) for treatment of conditions such as muscle wasting, osteoporosis and benign prostatic hypertrophy, using the non-steroidal androgen antagonist bicalutamide as a lead compound. Andarine is less potent in both anabolic and androgenic effects than other SARMs. Andarine exhibits potent and efficacious anabolic activity and results in dose-dependent stimulation of growth in prostate, seminal vesicles, and levator ani muscle with the ED50 of 0.43 mg/day, 0.55 mg/day, and 0.14 mg/day, respectively. Andarine reduced prostate weight with similar efficacy to finasteride, but without producing any reduction in muscle mass or anti-androgenic side effects. Andarine demonstrates tissue-selective pharmacological activity and significantly decreased prostate weight to 79.4% at a concentration of 0.5 mg/day in intact rats. Andarine (GTx-007) is able to competitively block binding of dihydrotestosterone to its receptor targets in the prostate gland.
| Molecular Weight | 441.36 |
| Formula | C19H18F3N3O6 |
| CAS Number | 401900-40-1 |
| Solubility (25°C) | DMSO 80 mg/mL Ethanol 80 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related Androgen Receptor Products |
|---|
| MDV3100
MDV3100 is an orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. |
| Bicalutamide
Bicalutamide is an orally active non-steroidal androgen receptor antagonist (IC50 = 190 nM). |
| Ostarine
Ostarine (GTx-024 and MK-2866) is an investigational selective androgen receptor modulator (SARM) with Ki of 3.8 nM. |
| AZD3514
AZD3514 is a potent, orally activie and selective androgen receptor (AR) inhibitor with potential anticancer cancer activity. |
| Apalutamide (ARN-509)
Apalutamide (ARN-509) is a novel androgen receptor (AR) antagonist for the treatment of castration-resistant prostate cancer (CRPC). |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
